

FIRST LIGHT

RESEARCH

InterGlobe Aviation | Target: Rs 1,100 | -31% | SELL Rising fuel costs to burn earnings; cut to SELL

Canara Bank | Target: Rs 150 | +14% | ADD Earnings beat but asset quality risks persist

RBL Bank | Target: Rs 195 | -9% | SELL Weak asset quality; elevated provisions - maintain SELL

Maruti Suzuki | **Target: Rs 6,900** | -9% | **SELL** Operational performance along expected lines; maintain SELL

TVS Motor | Target: Rs 350 | -34% | SELL

Valuations rich; maintain SELL

Coforge | Target: Rs 2,800 | +16% | BUY

Travel recovery and BFS drive growth

Eris Lifesciences | Target: Rs 730 | +17% | BUY

Healthy Q3; chronic franchise and FCF growth to unlock value

SUMMARY

InterGlobe Aviation

InterGlobe Aviation's (IndiGo) Q3FY21 RASK stood at Rs 3.2. EBITDA was at Rs 6.4bn but higher interest & depreciation led to a net loss of Rs 6.2bn. While IndiGo is poised for a revenue rebound given the easing of lockdowns, its market leadership (~55% share), ready capacity, sound balance sheet and firmer footing vis-à-vis peers, we believe the surge in crude costs will dent profits. We downgrade the stock from BUY to SELL as we cut FY23 PAT 45%, reset our EV/EBITDAR multiple down to 6.5x and roll over to a new Mar'22 TP of Rs 1,100 (vs. Rs 1,750).

Click here for the full report.

29 January 2021

TOP PICKS

LARGE-CAP IDEAS

Company	Rating Targe		
<u>Cipla</u>	Buy	900	
GAIL	Buy	155	
Petronet LNG	Buy	330	
<u>TCS</u>	Buy	3,710	
<u>Tech Mahindra</u>	Buy	1,040	

MID-CAP IDEAS

Company	Rating	Target
<u>Alkem Labs</u>	Buy	3,600
Greenply Industries	Buy	150
<u>Laurus Labs</u>	Buy	410
Transport Corp	Buy	300
<u>Mahanagar Gas</u>	Sell	750
	1	

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.02	(2bps)	9bps	(57bps)
India 10Y yield (%)	5.91	(1bps)	2bps	(67bps)
USD/INR	72.92	0	0.8	(2.3)
Brent Crude (US\$/bbl)	55.81	(0.2)	8.8	(6.7)
Dow	30,303	(2.0)	0.3	5.5
Shanghai	3,573	0.1	5.2	20.1
Sensex	47,410	(1.9)	0.9	15.1
India FII (US\$ mn)	25 Jan	MTD	CYTD	FYTD
FII-D	55.3	(369.7)	(369.7)	(4,463.3)
FII-E	40.7	3,183.6	3,183.6	33,159.4
C D			· D	1

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in





Canara Bank

Canara Bank's (CBK) Q3 PAT of Rs 7bn beat our estimate on strong 47% YoY growth in operating profit. Reported GNPA ratio declined to 7.5% but the proforma number stood at ~9%. The SMA-1 & 2 pool increased to 2.2% of loans (vs. 0.7% in Q2) and the overall implemented restructured book stood at 2.5%. Loan growth stayed subdued at 6% YoY. CBK's CASA ratio improved 60bps QoQ to 33.4%. We upgrade EPS estimates post Q3 and assign the stock a higher 0.5x P/BV multiple – on rollover, we have a new Mar'22 TP of Rs 150 (vs. Rs 115).

Click here for the full report.

RBL Bank

RBL Bank's (RBK) PAT was largely in line at Rs 1.5bn. Proforma GNPA ratio rose ~100bps QoQ to 4.6% driven by slippages of ~Rs 15bn, largely retail-led. RBK has adequately provided for the same by using contingent provisions. Stress in the micro banking and business loan portfolios is proving higher than anticipated. The restructured book stood at 0.9% and is guided to rise to 1.5% by Q4. We raise our TP to Rs 195 (vs. Rs 150) as we hike FY21-FY23 EPS 8-15%, roll to Mar'23 valuations and now assign the stock a 0.8x P/BV multiple.

Click here for the full report.

Maruti Suzuki

Maruti (MSIL) reported Q3FY21 earnings of Rs 19bn backed by higher other income and a lower tax rate. Revenue was slightly below estimates at Rs 235bn while EBITDA margin at 9.5% was in line. With expected revival and planned relaunch of diesel variants in FY22, we expect a monthly sales run-rate of ~150,000 vehicles in FY22. But the sharp spike in input costs is likely to exert heavy pressure on margins in the near-to-mid-term. We estimate a revenue/ PAT CAGR of 22%/35% over FY21-FY23 and retain our Mar'22 TP of Rs 6,900.

Click here for the full report.



TVS Motor

TVS Motor's (TVSL) Q3FY21 revenue was marginally better than estimated due to above-expected ASP. PAT came in at Rs 2.7bn vs. Rs 1.7bn forecast. Strong rural growth is expected to boost moped and motorcycle sales, though our channel checks suggest 3W sales have been badly hit and recovery may take longer than expected. We continue to bake in a volume CAGR of 11% during FY21-FY23, leading to a revenue/PAT CAGR of 13%/32%. Maintain SELL with an unchanged Mar'22 TP of Rs 350, based on 24x Mar'23E EPS.

Click here for the full report.

Coforge

Coforge reported a robust Q3FY21 performance, marked by 3.3% QoQ CC revenue growth led by the BFS and travel verticals. Operating margin was in line at 13% (-77bps QoQ). Management's FY21 outlook was positive backed by its highest ever executable order book of US\$ 501mn. We raise FY23 EPS by 4%, keeping FY22 EPS unchanged, and roll forward to a revised Dec'21 TP of Rs 2,800 (from Rs 2,690). Our target P/E stays unchanged at 22x given a robust deal pipeline and diversified revenue mix. Maintain BUY.

Click here for the full report.

Eris Lifesciences

Eris Lifesciences (ERIS) reported a healthy Q3 with a 3% revenue beat led by superior execution on the core cardio-metabolic and VMN portfolios (~78% of sales). Growth rebound in the acute portfolio (15% YoY vs. -1% for the covered market), upcoming high-value launches in Q4 and reduction in debtors were highlights. EBITDA margin stood at 34.5% (+572bps YoY on low base). ERIS expects 15% topline growth and margin expansion in FY22. We retain BUY and raise Mar'22 TP to Rs 730 (vs. Rs 700) as we tweak EPS estimates.

Click here for the full report.



SELL TP: Rs 1,100 | 🗡 31%

INTERGLOBE AVIATION

Airlines

Rising fuel costs to burn earnings; cut to SELL

InterGlobe Aviation's (IndiGo) Q3FY21 RASK stood at Rs 3.2. EBITDA was at Rs 6.4bn but higher interest & depreciation led to a net loss of Rs 6.2bn. While IndiGo is poised for a revenue rebound given the easing of lockdowns, its market leadership (~55% share), ready capacity, sound balance sheet and firmer footing vis-à-vis peers, we believe the surge in crude costs will dent profits. We downgrade the stock from BUY to SELL as we cut FY23 PAT 45%, reset our EV/EBITDAR multiple down to 6.5x and roll over to a new Mar²22 TP of Rs 1,100 (vs. Rs 1,750).

Disappointing Q3: Revenue plunged 51% YoY to Rs 49.1bn in Q3. RASK was in line with our estimate at Rs 3.2 (excluding other income). Management mentioned that while the earlier part of the quarter reported strong RASK, the latter period saw some pressure which impacted profitability. EBITDA totalled Rs 6.4bn but IndiGo reported an adjusted net loss of Rs 6.2bn owing to higher interest and depreciation costs.

Expect steady growth recovery but rising fuel costs to erode profits: We

believe IndiGo is in a sweet spot for growth over the next two years given a benign USDINR, the vulnerability of most of its peers (in terms of negative net worth and massive cash burn), and a strong balance sheet. Nevertheless, the sharp jump in crude cost is expected to severely erode profitability in the near-to-mid-term

Cut to SELL: Despite assuming sharp traffic growth and improvement in RASK, surging crude prices prompt us to slash our FY23 PAT estimate by 45%. We now value IndiGo at 6.5x adj. EV/EBITDAR (earlier 9x) and roll valuations forward to Mar'23, translating to a reduced target price of Rs 1,100 (earlier Rs 1,750). Downgrade from BUY to SELL.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E	
Total revenue (Rs mn)	284,968	357,560	150,742	332,082	427,555	
EBITDA (Rs mn)	(5,354)	40,382	(1,555)	42,059	65,151	
Adj. net profit (Rs mn)	(2,283)	(2,482)	(52,717)	(6,675)	14,636	
Adj. EPS (Rs)	(5.9)	(6.4)	(137.0)	(17.3)	38.0	
Adj. EPS growth (%)	NA	NA	NA	NA		
Adj. ROAE (%)	(3.3)	(4.2)	(892.4)	78.9	(272.5)	
Adj. P/E (x)	(268.2)	(247.0)	(11.6)	(91.8)	41.9	
EV/EBITDA (x)	(102.8)	13.0	(333.5)	14.2	9.8	

Source: Company, BOBCAPS Research

28 January 2021

Mayur Milak | Nishant Chowhan, CFA research@bobcaps.in

Ticker/Price	INDIGO IN/Rs 1,593
Market cap	US\$ 8.4bn
Shares o/s	385mn
3M ADV	US\$ 39.0mn
52wk high/low	Rs 1,787/Rs 771
Promoter/FPI/DII	75%/15%/7%
Source: NSE	

STOCK PERFORMANCE







ADD TP: Rs 150 | ▲ 14%

CANARA BANK

Banking

Earnings beat but asset quality risks persist

Canara Bank's (CBK) Q3 PAT of Rs 7bn beat our estimate on strong 47% YoY growth in operating profit. Reported GNPA ratio declined to 7.5% but the proforma number stood at ~9%. The SMA-1 & 2 pool increased to 2.2% of loans (vs. 0.7% in Q2) and the overall implemented restructured book stood at 2.5%. Loan growth stayed subdued at 6% YoY. CBK's CASA ratio improved 60bps QoQ to 33.4%. We upgrade EPS estimates post Q3 and assign the stock a higher 0.5x P/BV multiple – on rollover, we have a new Mar'22 TP of Rs 150 (vs. Rs 115).

Proforma GNPAs rise sharply: CBK's proforma GNPA ratio stood at ~9%, marking a high divergence of ~150bps from the reported figure owing to proforma slippages worth ~Rs 100bn. The bank has conservatively reversed interest worth Rs 4bn and provided ~Rs 19bn on proforma slippages. Collection efficiency stood at 95% in Q3. The SMA-1 & 2 pool swelled to 2.2% of loans, and CBK's restructured book stood at ~Rs 160bn (2.5% of loans) with a large portion driven by corporates, especially a big steel account.

Growth remains subdued: Loan growth stood at ~6% YoY given lacklustre 2% growth in the corporate portfolio. However, the RAM (retail + agri + MSME) portfolio grew 9%. Management expects credit growth to hover between 6% and 8% in FY21. Of the overall sanctioned pool of Rs 100bn, CBK has disbursed ~Rs 95bn under ECLGS. Deposits grew 8% YoY with ~15% growth in CASA deposits but an ~11% decline in bulk funds.

Maintain ADD: We raise our FY21-FY23 EPS sharply to factor in the Q3 beat but continue to believe that elevated provisions will keep ROA/ROE subdued at ~0.3%/~5% by FY23. Valuing the stock at 0.5x P/BV (vs. 0.4x earlier), we roll over to a new Mar'22 TP of Rs 150. Maintain ADD.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Net interest income	144,781	131,239	246,481	272,365	303,356
NII growth (%)	19.0	(9.4)	87.8	10.5	11.4
Adj. net profit (Rs mn)	3,470	(22,357)	21,238	22,715	27,556
EPS (Rs)	4.7	(25.1)	14.3	11.7	14.2
P/E (x)	28.1	(5.2)	9.2	11.2	9.3
P/BV (x)	0.3	0.3	0.4	0.4	0.4
ROA (%)	0.1	(0.3)	0.2	0.2	0.2
ROE (%)	1.0	(5.9)	4.3	3.7	4.3

Source: Company, BOBCAPS Research

28 January 2021

Vikesh Mehta

research@bobcaps.in

Ticker/Price	CBK IN/Rs 131
Market cap	US\$ 2.6bn
Shares o/s	1,454mn
3M ADV	US\$ 44.5mn
52wk high/low	Rs 212/Rs 74
Promoter/FPI/DII	79%/3%/18%
Source: NSE	

STOCK PERFORMANCE







SELL TP: Rs 195 | ♥ 9%

RBL BANK

Banking

Weak asset quality; elevated provisions - maintain SELL

RBL Bank's (RBK) PAT was largely in line at Rs 1.5bn. Proforma GNPA ratio rose ~100bps QoQ to 4.6% driven by slippages of ~Rs 15bn, largely retail-led. RBK has adequately provided for the same by using contingent provisions. Stress in the micro banking and business loan portfolios is proving higher than anticipated. The restructured book stood at 0.9% and is guided to rise to 1.5% by Q4. We raise our TP to Rs 195 (vs. Rs 150) as we hike FY21-FY23 EPS 8-15%, roll to Mar'23 valuations and now assign the stock a 0.8x P/BV multiple.

Stress on asset quality yet to run its course: RBK's proforma GNPA ratio climbed sharply to 4.6% (vs. 3.5% in Q2) owing to elevated slippages worth Rs 14.7bn emerging primarily from the retail portfolio (Rs 13bn). Proforma GNPA ratio in the credit card portfolio was at 5.7% and the bank expects it to remain stable in Q4. But the micro banking/business loan portfolios could see increases from 2.6%/4.5% currently to ~5.5%/6% in Q4. The bank has used ~50% of its Q2 contingency buffer to the extent of ~Rs 3bn. Collection efficiency is back to pre-Covid levels in the credit card portfolio, stable in the micro banking business at 92%, and at 96% of normal levels in business loans.

Growth remains elusive: RBK's loan book declined 5% YoY given a 25% drop in the wholesale portfolio. Retail advances grew 16% YoY with 30% growth in the credit card portfolio. The new card business has returned to pre-Covid levels and its market share has improved to 4.8%. However, the bank remains cautious on growth in the micro banking and business loan portfolios. NIM declined 15bps QoQ to 4.2% due to interest reversals.

Maintain SELL: We continue to believe that higher credit costs will keep ROE subdued (at ~10% by FY23E). Valuing the stock at 0.8x P/BV (0.6x earlier), we roll to a new Mar'22 TP of Rs 195.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Net interest income	25,395	36,296	37,809	42,195	49,320
NII growth (%)	43.8	42.9	4.2	11.6	16.9
Adj. net profit (Rs mn)	8,670	5,057	5,570	10,622	14,604
EPS (Rs)	20.5	10.8	10.1	17.8	24.4
P/E (x)	10.5	19.9	21.4	12.1	8.8
P/BV (x)	1.2	1.0	1.0	1.0	0.9
ROA (%)	1.2	0.6	0.6	1.0	1.2
ROE (%)	12.2	5.6	4.8	8.1	10.4

Source: Company, BOBCAPS Research


28 January 2021

Vikesh Mehta

research@bobcaps.in

Ticker/Price	RBK IN/Rs 215
Market cap	US\$ 1.5bn
Shares o/s	509mn
3M ADV	US\$ 60.1mn
52wk high/low	Rs 347/Rs 102
Promoter/FPI/DII	0%/29%/71%
Source: NSE	

STOCK PERFORMANCE







SELL TP: Rs 6,900 | ♥ 9%

MARUTI SUZUKI

Automobiles

Operational performance along expected lines; maintain SELL

Maruti (MSIL) reported Q3FY21 earnings of Rs 19bn backed by higher other income and a lower tax rate. Revenue was slightly below estimates at Rs 235bn while EBITDA margin at 9.5% was in line. With expected revival and planned relaunch of diesel variants in FY22, we expect a monthly sales run-rate of ~150,000 vehicles in FY22. But the sharp spike in input costs is likely to exert heavy pressure on margins in the near-to-mid-term. We estimate a revenue/ PAT CAGR of 22%/35% over FY21-FY23 and retain our Mar²22 TP of Rs 6,900.

In-line operating performance: At Rs 234.6bn (+13% YoY), MSIL's revenue was ~3% lower than our estimate, affected by softer ASP due to higher sales promotion expenses. EBITDA margin at 9.5% was in line with our projection, leading to EBITDA growth of 6% YoY to Rs 22.3bn. Adj. PAT for Q3 grew ahead of estimates at 24% YoY to Rs 19.4bn due to higher-than-expected treasury income and a lower tax rate of 21% (~25% estimated).

Spike in input costs to depress margins: Steel forms ~60% of the raw material used in a car. Since Sep'20, steel prices have surged >90% (from ~US\$ 540/t to >US\$ 1,000), which can have a devastating impact on margins. Even if steel averages at US\$ 750-800, MSIL will need to hike prices by over 15% to maintain Q2FY21 margins (10.3%).

Maintain SELL: Our revenue forecasts are higher than the street, limiting any positive surprise from volume growth. After the steep >10% price increase taken by most automakers due to BSVI transition, we see little scope for further sharp hikes, implying the raw material cost burden will erode margins in the near-to-medium term. The street's view of gross margin expansion in FY22 and FY23 looks overstated. We maintain our Mar'22 TP of Rs 6,900 set at 26x FY23E EPS and recommend SELL.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	860,203	756,106	688,350	927,746	1,027,015
EBITDA (Rs mn)	109,993	73,026	53,144	87,940	101,416
Adj. net profit (Rs mn)	91,700	56,506	43,697	68,497	79,834
Adj. EPS (Rs)	193.0	187.1	144.7	226.8	264.3
Adj. EPS growth (%)	(8.9)	(3.1)	(22.7)	56.8	16.6
Adj. ROAE (%)	13.3	11.9	8.8	12.9	13.7
Adj. P/E (x)	39.3	40.6	52.5	33.5	28.7
EV/EBITDA (x)	20.8	31.2	42.9	26.0	22.6

Source: Company, BOBCAPS Research

28 January 2021

Mayur Milak | Nishant Chowhan, CFA research@bobcaps.in

Ticker/Price	MSIL IN/Rs 7,589
Market cap	US\$ 31.4bn
Shares o/s	302mn
3M ADV	US\$ 117.9mn
52wk high/low	Rs 8,329/Rs 4,001
Promoter/FPI/DII	56%/21%/17%
Source: NSE	

STOCK PERFORMANCE





SELL TP: Rs 350 | ▼ 34% TVS MOTOR

Automobiles

28 January 2021

Mayur Milak | Nishant Chowhan, CFA

research@bobcaps.in

Valuations rich; maintain SELL

TVS Motor's (TVSL) Q3FY21 revenue was marginally better than estimated due to above-expected ASP. PAT came in at Rs 2.7bn vs. Rs 1.7bn forecast. Strong rural growth is expected to boost moped and motorcycle sales, though our channel checks suggest 3W sales have been badly hit and recovery may take longer than expected. We continue to bake in a volume CAGR of 11% during FY21-FY23, leading to a revenue/PAT CAGR of 13%/32%. Maintain SELL with an unchanged Mar'22 TP of Rs 350, based on 24x Mar'23E EPS.

Beat on margins: Q3 revenue grew 31% YoY to Rs 53.9bn as ASPs increased 9% led by BSVI upgrades while volumes rose 20%. Despite the steep increase in raw material prices, TVSL posted gross margin expansion QoQ coupled with better operating efficiency, which supported an EBITDA margin beat (9.5% vs. 7.7% est.). EBITDA grew 41% YoY to Rs 5.1bn and adj. PAT was up 35% YoY to Rs 2.7bn (Rs 1.7bn est.)

Consensus margins at high risk of downgrade: Our revenue forecasts are similar to the street. After the recent price increases taken due to BSVI transition and cost escalation, we see little scope for further sharp hikes, implying the raw material cost burden will erode margins in the near-to-medium term. The general view of gross margin expansion in FY22 and FY23 leaves us skeptical of current valuations, which are running much ahead of long-term averages. We expect sharp downgrades to consensus estimates as commodity prices stabilise.

Valuations expensive: ROCE/ROE are forecast at 12%/14% by FY23. At CMP, the stock is trading at 37x FY23E EPS which looks rich. Our TP remains unchanged at Rs 350 and is based on 24x FY23E EPS; maintain SELL.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	182,099	164,233	159,070	185,461	203,829
EBITDA (Rs mn)	14,332	13,459	11,736	14,657	16,201
Adj. net profit (Rs mn)	6,701	6,246	3,952	5,902	6,861
Adj. EPS (Rs)	14.1	12.5	8.3	12.4	14.4
Adj. EPS growth (%)	3.9	(11.8)	(33.3)	49.4	16.2
Adj. ROAE (%)	20.0	17.3	10.1	13.6	14.3
Adj. P/E (x)	37.4	42.4	63.6	42.6	36.6
EV/EBITDA (x)	17.6	18.7	21.1	16.8	15.4

Source: Company, BOBCAPS Research

Ticker/Price	TVSL IN/Rs 529
Market cap	US\$ 3.4bn
Shares o/s	475mn
3M ADV	US\$ 21.6mn
52wk high/low	Rs 556/Rs 240
Promoter/FPI/DII	57%/11%/22%
Source: NSF	

STOCK PERFORMANCE







BUY TP: Rs 2,800 | A 16%

COFORGE

IT Services

28 January 2021

Ruchi Burde | Seema Nayak

research@bobcaps.in

Travel recovery and BFS drive growth

Coforge reported a robust Q3FY21 performance, marked by 3.3% QoQ CC revenue growth led by the BFS and travel verticals. Operating margin was in line at 13% (-77bps QoQ). Management's FY21 outlook was positive backed by its highest ever executable order book of US\$ 501mn. We raise FY23 EPS by 4%, keeping FY22 EPS unchanged, and roll forward to a revised Dec'21 TP of Rs 2,800 (from Rs 2,690). Our target P/E stays unchanged at 22x given a robust deal pipeline and diversified revenue mix. Maintain BUY.

Growth and margins in line: Coforge declared revenue growth of 3.3% QoQ CC, meeting our estimate. Growth was driven by a ~9% QoQ increase in both the BFS and travel verticals, marking a strong rebound in travel. Insurance was weak with a decline of 2.9% QoQ in reported terms, following accelerated growth of 12.5% in Q2FY21. EBIT margin was in line at 13%, down 77bps QoQ due to lower utilisation and selective wage hikes to control attrition.

Strong order intake: Fresh order intake totalled US\$ 193mn, leading to a record-high US\$ 501mn executable order book (+2% QoQ, +18% YoY) over the next 12 months – crossing the US\$ 500mn mark for the first time. Of the US\$ 193mn order book, US\$ 116mn came from the US, US\$ 45mn from EMEA and US\$ 32mn from RoW. Two large deals were signed – one each in the insurance space (worth US\$ 45mn) and healthcare vertical.

Upbeat outlook: After a robust revenue growth and margin performance in Q3, management expects FY21 growth to be at least 6.3% CC. EBIT margin guidance for the year has been revised slightly upwards to 18% from 17.8% earlier (before RSU cost). This guidance includes the impact from impending wage hikes for the rest of the staff.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	36,762	41,839	47,097	59,263	68,540
EBITDA (Rs mn)	6,453	7,431	8,124	10,352	11,937
Adj. net profit (Rs mn)	4,089	4,539	4,803	7,142	8,102
Adj. EPS (Rs)	66.2	73.5	77.7	115.6	131.1
Adj. EPS growth (%)	45.9	11.0	5.8	48.7	13.4
Adj. ROAE (%)	20.3	18.7	17.3	22.6	22.1
Adj. P/E (x)	36.6	32.9	31.1	20.9	18.5
EV/EBITDA (x)	22.6	19.3	17.1	13.0	10.9

Source: Company, BOBCAPS Research

Ticker/PriceCOFORGE IN/
Rs 2,420Market capUS\$ 2.0bnShares o/s62mn3M ADVUS\$ 15.6mn52wk high/lowRs 2,910/Rs 735Promoter/FPI/DII70%/13%/17%Source: NSE

STOCK PERFORMANCE





BUY TP: Rs 730 | 🔺 17%

ERIS LIFESCIENCES

Pharmaceuticals

Healthy Q3; chronic franchise and FCF growth to unlock value

Eris Lifesciences (ERIS) reported a healthy Q3 with a 3% revenue beat led by superior execution on the core cardio-metabolic and VMN portfolios (~78% of sales). Growth rebound in the acute portfolio (15% YoY vs. -1% for the covered market), upcoming high-value launches in Q4 and reduction in debtors were highlights. EBITDA margin stood at 34.5% (+572bps YoY on low base). ERIS expects 15% topline growth and margin expansion in FY22. We retain BUY and raise Mar'22 TP to Rs 730 (vs. Rs 700) as we tweak EPS estimates.

Strong FY22 sales guidance backed by organic portfolio: Q3 revenue growth of 16.5% YoY came on the back of a 14%/37% rise in the cardio-metabolic and VMN segments. ZAC D (launched in Q2) led to stellar growth in VMN. ERIS is guiding for 15% sales growth in FY22 steered by the organic portfolio (new launches, doctor reach expansion, higher MR productivity). It has launched three brands in Q3 (incl. Dapagliflozin in the SGLT 2 segment, Rivaroxaban) and expects Rs 1bn in sales each over five years. We continue to believe strong product selection, emerging off-patent upsides in cardio-diabetes, Zomelis scale-up and Rx penetration in the cardiac and VMN segments would support ~13% sales CAGR over FY21-FY24 (>16% in chronic).

Q3 margins set to expand; OCF conversion stays strong: Gross margins expanded 120bps QoQ to 82% and EBITDA margins were at 34.5% (-330bps QoQ) on higher SGA spends. Management expects to retain margins in Q4 but to see operating leverage from launches in FY22. The Guwahati plant is utilised ~40% on a 3-shift basis. OCF/EBITDA conversion was at 93%.

Earnings call takeaways: (1) Expect three launches in Q4 (incl. Dapagliflozin + Metformin combo). (2) Debtors at 43 days in Q3; target of 30 days by FY22.
(3) Zomelis tracking at Rs 400mn annually. (4) Limited M&A bandwidth.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	9,822	10,741	11,903	13,566	15,355
EBITDA (Rs mn)	3,449	3,684	4,174	4,971	5,806
Adj. net profit (Rs mn)	2,908	2,965	3,346	4,113	4,910
Adj. EPS (Rs)	21.4	21.8	24.6	30.3	36.2
Adj. EPS growth (%)	(1.1)	2.0	12.9	22.9	19.4
Adj. ROAE (%)	31.1	26.5	25.7	26.0	25.5
Adj. P/E (x)	29.1	28.5	25.3	20.6	17.2
EV/EBITDA (x)	24.5	23.1	19.9	16.5	13.6

Source: Company, BOBCAPS Research

28 January 2021

Vivek Kumar | Saad Shaikh research@bobcaps.in

Ticker/Price	ERIS IN/Rs 623
Market cap	US\$ 1.2bn
Shares o/s	136mn
3M ADV	US\$1.4mn
52wk high/low	Rs 643/Rs 321
Promoter/FPI/DII	54%/11%/11%
Source: NSE	

STOCK PERFORMANCE







Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 31 December 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 14 have ADD ratings, 6 are rated REDUCE and 25 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

FIRST LIGHT



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.